Product image of Korjuny (Catumaxomab) supplied by GNH India

Korjuny

Active Ingredient:
Catumaxomab
Origin:
EU

Korjuny (Catumaxomab)

Catumaxomab, the active ingredient in Korjuny, is a monoclonal antibody presented as a solution for injection for intraperitoneal use. It is indicated for the management of malignant ascites associated with epithelial cancers in adult patients, helping to control fluid accumulation and improve quality of life.

GNH India supplies Korjuny as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Customers benefit from reliable logistics and temperature‑controlled shipping where required.

Manufacturer / TM Owner

Atnahs Pharma Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Korjuny (catumaxomab) is used in the management of malignant ascites, a fluid accumulation condition linked to epithelial cancers that express EpCAM.
  • Malignant ascites associated with epithelial cancers: reduces peritoneal fluid buildup and improves symptomatic relief.
  • Ovarian carcinoma with malignant ascites: helps control peritoneal fluid and may improve patient comfort.
  • Gastric carcinoma with malignant ascites: reduces ascitic volume and supports palliative management.
  • Pancreatic carcinoma with malignant ascites: assists in decreasing fluid accumulation and alleviating symptoms.
  • Other EpCAM‑positive epithelial cancers with malignant ascites: provides immunologic targeting to reduce fluid buildup.
  • EpCAM‑positive colorectal carcinoma with malignant ascites: contributes to fluid reduction and symptom control.

How It Works

  • Catumaxomab is a bispecific monoclonal antibody that simultaneously binds epithelial cell adhesion molecule (EpCAM) on tumor cells and CD3 on T‑lymphocytes. This dual binding creates an immunological synapse, activating T cells and directing them to EpCAM‑expressing cancer cells within the peritoneal cavity, leading to cytokine release and tumor cell lysis, thereby reducing ascitic fluid production. The localized immune response limits systemic exposure while enhancing clearance of malignant cells from the peritoneal space.

Side Effects

Catumaxomab may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Fever: transient elevated body temperature.
  • Abdominal pain: discomfort in the peritoneal region.
  • Nausea and vomiting: gastrointestinal upset.
  • Diarrhea: loose stools.

Serious or Rare Side Effects

  • Cytokine release syndrome: systemic inflammatory response that can be life‑threatening.
  • Severe infection: peritonitis or sepsis requiring hospitalization.
  • Allergic reactions: anaphylaxis or severe hypersensitivity.
  • Hepatic dysfunction: elevated liver enzymes or liver injury.

Precautions & Warnings

  • When using Korjuny, clinicians should observe specific precautions to ensure patient safety and product integrity.
  • Patient selection: confirm EpCAM‑positive tumor status before administration.
  • Monitoring: observe for signs of cytokine release and manage fever promptly.
  • Infection risk: assess for active infections and provide prophylactic measures as needed.
  • Pregnancy and lactation: avoid use due to unknown safety profile in pregnant or breastfeeding women.
  • Concomitant immunosuppression: evaluate risks when combined with other immunosuppressive agents.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Catumaxomab can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Live vaccines: concurrent use may trigger severe immune reactions.
  • Other monoclonal antibodies targeting immune cells: may increase risk of excessive immunosuppression.
  • High‑dose corticosteroids: can diminish therapeutic activity.

Moderate Interactions (Monitor Closely)

  • Chemotherapy agents: monitor for additive toxicity, especially hematologic effects.
  • Anticoagulants: watch for bleeding complications due to potential platelet activation changes.
  • Immunosuppressive drugs (e.g., azathioprine): may require dose adjustments.

Frequently Asked Questions

Korjuny, containing the monoclonal antibody catumaxomab, is indicated for the treatment of malignant ascites that develop in patients with EpCAM‑positive epithelial cancers. It helps reduce peritoneal fluid accumulation and can improve symptom control and quality of life.

Catumaxomab is a bispecific antibody that binds EpCAM on tumor cells and CD3 on T‑lymphocytes. This creates an immune synapse that activates T cells, directing them to attack EpCAM‑expressing cancer cells in the peritoneal cavity, leading to cytokine release and tumor cell lysis.

The dose and administration schedule of Korjuny are determined by the treating physician based on the patient’s clinical condition, tumor type, and regulatory guidelines. No fixed dosing regimen is publicly disclosed; prescribers tailor therapy to individual needs.

Safety of catumaxomab in pregnant or lactating women has not been established. Because the drug’s effects on the fetus or nursing infant are unknown, it is generally avoided in these populations unless the potential benefit outweighs the risk.

To request Korjuny, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Korjuny offers a targeted immunotherapeutic approach by engaging the patient’s own T cells, whereas conventional options such as repeated paracentesis, diuretics, or systemic chemotherapy provide symptomatic relief without specific immune activation. Catumaxomab’s bispecific mechanism can achieve longer‑lasting control of fluid buildup in EpCAM‑positive cancers.

Korjuny must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Proper cold‑chain handling is essential to maintain product stability and efficacy.

Korjuny is supplied as a sterile solution for injection and is administered intraperitoneally by a qualified healthcare professional. The drug is injected directly into the peritoneal cavity, allowing localized exposure to malignant cells.

The most critical adverse events include cytokine release syndrome, severe infections such as peritonitis or sepsis, and serious allergic reactions including anaphylaxis. Prompt recognition and management of these conditions are essential during treatment.

Korjuny should be avoided in patients with known hypersensitivity to catumaxomab or any component of the formulation, those with active uncontrolled infections, pregnant or breastfeeding women, and individuals for whom EpCAM expression on the tumor has not been confirmed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Catumaxomab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT